Amazon Stock Rebounds After Earnings as $200B Capex Plan Sparks AI Spending Debate 
California Jury Awards $40 Million in Johnson & Johnson Talc Cancer Lawsuit 
SpaceX Pivots Toward Moon City as Musk Reframes Long-Term Space Vision 
Global PC Makers Eye Chinese Memory Chip Suppliers Amid Ongoing Supply Crunch 
Sony Q3 Profit Jumps on Gaming and Image Sensors, Full-Year Outlook Raised 
NASA Astronauts Wilmore and Williams Recover After Boeing Starliner Delay 
Dollar Near Two-Week High as Stock Rout, AI Concerns and Global Events Drive Market Volatility 
Uber Ordered to Pay $8.5 Million in Bellwether Sexual Assault Lawsuit 
NASA Partners with Katalyst to Save Swift Observatory with Innovative Docking Mission 
FDA Fast-Tracks Approval of Altria’s on! PLUS Nicotine Pouches Under New Pilot Program 
U.S. Stock Futures Rise as Markets Brace for Jobs and Inflation Data 
Toyota’s Surprise CEO Change Signals Strategic Shift Amid Global Auto Turmoil 
Neuralink Plans High-Volume Brain Implant Production and Fully Automated Surgery by 2026 
Indian Refiners Scale Back Russian Oil Imports as U.S.-India Trade Deal Advances 
Bank of Japan Signals Readiness for Near-Term Rate Hike as Inflation Nears Target 
Sanofi’s Efdoralprin Alfa Gains EMA Orphan Status for Rare Lung Disease 
Fujirebio Holding is now doubling down on developing blood tests to detect Alzheimer’s against which blockbuster therapy is expected soon.
The tiny Tokyo-based diagnostics firm, a unit of H.U. Group Holdings, which has a market value of $1.2 billion, developed the first US-approved spinal fluid test for Alzheimer’s.
According to Goki Ishikawa, the CEO of Fujirebio, the firm is boosting its lineup of reagents used to detect Alzheimer’s biomarkers in blood tests. It aims to file these tests for approval in the US as early as 2023.
Ishikawa said that the lineups offered by industry leaders are still limited, so they are rushing to create a solid lineup of tests.
